MovDisordV3, Main, Exploration, bibRecord, 005319

Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride

Identifieur interne : 005319 ( Main/Exploration ); précédent : 005318; suivant : 005320

Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride

Auteurs : Angelo Antonini [Suisse] ; Johannes Schwarz [Suisse] ; Wolfgang H. Oertel [Suisse] ; Oliver Pogarell [Suisse] ; Leenders [Suisse, Allemagne]

Source :

Movement Disorders [ 0885-3185 ] ; 1997-01.

RBID : ISTEX:B6E9D4BE9B82257D2DDDF0C976C381F6BA037634

Descripteurs français

Pascal (Inist)
- Antagoniste dopamine, Corps strié, Exploration, Homme, Long terme, Neuroleptique, Parkinson maladie, Positon, Psychotrope, Raclopride, Récepteur dopaminergique D2, Tomoscintigraphie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Caudate Nucleus (drug effects), Caudate Nucleus (physiopathology), Caudate Nucleus (radionuclide imaging), Corpus Striatum (drug effects), Corpus Striatum (physiopathology), Corpus Striatum (radionuclide imaging), Corpus striatum, D2 Dopamine receptor, Dopamine Agonists (therapeutic use), Dopamine Antagonists (pharmacokinetics), Dopamine D2 receptors, Dopamine antagonist, Drug Therapy, Combination, Emission tomography, Exploration, Female, Follow-Up Studies, Human, Humans, Levodopa (therapeutic use), Long term, Longitudinal Studies, Male, Middle Aged, Neural Pathways (drug effects), Neural Pathways (physiopathology), Neural Pathways (radionuclide imaging), Neuroleptic, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (radionuclide imaging), Parkinson disease, Parkinson's disease, Positron, Positron emission tomography, Psychotropic, Putamen (drug effects), Putamen (physiopathology), Putamen (radionuclide imaging), Raclopride, Receptors, Dopamine D2 (drug effects), Receptors, Dopamine D2 (physiology), Salicylamides (pharmacokinetics), Substantia Nigra (drug effects), Substantia Nigra (physiopathology), Substantia Nigra (radionuclide imaging), Tomography, Emission-Computed, [11C]Raclopride.
MESH :
- chemical , drug effects : Receptors, Dopamine D2.
- chemical , pharmacokinetics : Dopamine Antagonists, Salicylamides.
- chemical , physiology : Receptors, Dopamine D2.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- drug effects : Caudate Nucleus, Corpus Striatum, Neural Pathways, Putamen, Substantia Nigra.
- drug therapy : Parkinson Disease.
- physiopathology : Caudate Nucleus, Corpus Striatum, Neural Pathways, Parkinson Disease, Putamen, Substantia Nigra.
- radionuclide imaging : Caudate Nucleus, Corpus Striatum, Neural Pathways, Parkinson Disease, Putamen, Substantia Nigra.
- Aged, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Raclopride, Tomography, Emission-Computed.

Abstract

We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug‐naive stage and 3–5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p < 0.04). The caudate nucleus revealed values in the normal range. After 3–5 years, RACLO binding was significantly reduced in the putamen (p < 0.03) and caudate nucleus (p < 0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p < 0.05). The clinical score at “off” had significantly worsened (p < 0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3–4 months after therapy began and at that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long‐term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons.

Url:

https://api.istex.fr/document/B6E9D4BE9B82257D2DDDF0C976C381F6BA037634/fulltext/pdf

DOI: 10.1002/mds.870120107

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride</title>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
</author>
<author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
</author>
<author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name>
</author>
<author><name sortKey="Leenders" sort="Leenders" uniqKey="Leenders" last="Leenders">Leenders</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B6E9D4BE9B82257D2DDDF0C976C381F6BA037634</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1002/mds.870120107</idno>
<idno type="url">https://api.istex.fr/document/B6E9D4BE9B82257D2DDDF0C976C381F6BA037634/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001697</idno>
<idno type="wicri:Area/Istex/Curation">001697</idno>
<idno type="wicri:Area/Istex/Checkpoint">003943</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Antonini A:long:term:changes</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8990051</idno>
<idno type="wicri:Area/PubMed/Corpus">004735</idno>
<idno type="wicri:Area/PubMed/Curation">004735</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004631</idno>
<idno type="wicri:Area/Ncbi/Merge">004C48</idno>
<idno type="wicri:Area/Ncbi/Curation">004C48</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004C48</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Antonini A:long:term:changes</idno>
<idno type="wicri:Area/Main/Merge">008348</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:97-0142918</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003304</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003520</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003203</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Antonini A:long:term:changes</idno>
<idno type="wicri:Area/Main/Merge">008558</idno>
<idno type="wicri:Area/Main/Curation">005319</idno>
<idno type="wicri:Area/Main/Exploration">005319</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride</title>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich</wicri:regionArea>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Department of Neurology, University Hospital Zurich, Zurich</wicri:regionArea>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Department of Neurology, University Hospital Zurich, Zurich</wicri:regionArea>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Department of Neurology, University Hospital Zurich, Zurich</wicri:regionArea>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Leenders" sort="Leenders" uniqKey="Leenders" last="Leenders">Leenders</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich</wicri:regionArea>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1997-01">1997-01</date>
<biblScope unit="vol">12</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="33">33</biblScope>
<biblScope unit="page" to="38">38</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">B6E9D4BE9B82257D2DDDF0C976C381F6BA037634</idno>
<idno type="DOI">10.1002/mds.870120107</idno>
<idno type="ArticleID">MDS870120107</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Caudate Nucleus (drug effects)</term>
<term>Caudate Nucleus (physiopathology)</term>
<term>Caudate Nucleus (radionuclide imaging)</term>
<term>Corpus Striatum (drug effects)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>Corpus Striatum (radionuclide imaging)</term>
<term>Corpus striatum</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dopamine Antagonists (pharmacokinetics)</term>
<term>Dopamine D2 receptors</term>
<term>Dopamine antagonist</term>
<term>Drug Therapy, Combination</term>
<term>Emission tomography</term>
<term>Exploration</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Long term</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neural Pathways (drug effects)</term>
<term>Neural Pathways (physiopathology)</term>
<term>Neural Pathways (radionuclide imaging)</term>
<term>Neuroleptic</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (radionuclide imaging)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Positron</term>
<term>Positron emission tomography</term>
<term>Psychotropic</term>
<term>Putamen (drug effects)</term>
<term>Putamen (physiopathology)</term>
<term>Putamen (radionuclide imaging)</term>
<term>Raclopride</term>
<term>Receptors, Dopamine D2 (drug effects)</term>
<term>Receptors, Dopamine D2 (physiology)</term>
<term>Salicylamides (pharmacokinetics)</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia Nigra (physiopathology)</term>
<term>Substantia Nigra (radionuclide imaging)</term>
<term>Tomography, Emission-Computed</term>
<term>[11C]Raclopride</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Dopamine Antagonists</term>
<term>Salicylamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Caudate Nucleus</term>
<term>Corpus Striatum</term>
<term>Neural Pathways</term>
<term>Putamen</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Caudate Nucleus</term>
<term>Corpus Striatum</term>
<term>Neural Pathways</term>
<term>Parkinson Disease</term>
<term>Putamen</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Caudate Nucleus</term>
<term>Corpus Striatum</term>
<term>Neural Pathways</term>
<term>Parkinson Disease</term>
<term>Putamen</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Raclopride</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste dopamine</term>
<term>Corps strié</term>
<term>Exploration</term>
<term>Homme</term>
<term>Long terme</term>
<term>Neuroleptique</term>
<term>Parkinson maladie</term>
<term>Positon</term>
<term>Psychotrope</term>
<term>Raclopride</term>
<term>Récepteur dopaminergique D2</term>
<term>Tomoscintigraphie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug‐naive stage and 3–5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p < 0.04). The caudate nucleus revealed values in the normal range. After 3–5 years, RACLO binding was significantly reduced in the putamen (p < 0.03) and caudate nucleus (p < 0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p < 0.05). The clinical score at “off” had significantly worsened (p < 0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3–4 months after therapy began and at that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long‐term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Suisse</li>
</country>
<region><li>Bavière</li>
<li>District de Haute-Bavière</li>
</region>
<settlement><li>Munich</li>
</settlement>
</list>
<tree><country name="Suisse"><noRegion><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
</noRegion>
<name sortKey="Leenders" sort="Leenders" uniqKey="Leenders" last="Leenders">Leenders</name>
<name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name>
<name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name>
</country>
<country name="Allemagne"><region name="Bavière"><name sortKey="Leenders" sort="Leenders" uniqKey="Leenders" last="Leenders">Leenders</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005319 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005319 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:B6E9D4BE9B82257D2DDDF0C976C381F6BA037634
   |texte=   Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride

Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.